Across India’s pediatric healthcare system, delays in identifying neurodevelopmental conditions continue to shape long-term outcomes for children. Limited access to specialists, long wait times, and uneven infrastructure mean that conditions such as autism and ADHD are often detected later than clinically ideal.
Gabify is entering this gap with an AI-led approach designed to compress diagnosis timelines while maintaining clinical accuracy. The New Delhi-based startup has raised $175,000 in a pre-seed round led by Inflection Point Ventures, alongside a government-backed grant under the Nidhi Seed Support Scheme.
The funding will be used to advance clinical validation, enhance its AI systems, and expand its team as the company moves toward broader deployment.
Building an AI layer over clinical workflows
Dual-AI system designed for real-world diagnosis
Gabify’s platform combines voice and vision AI to assess children across multiple dimensions. It analyzes speech patterns alongside facial expressions, eye gaze, and behavioral indicators, using more than 189 clinically validated parameters aligned with DSM-5 and CARS frameworks.
This approach reflects a shift away from single-input diagnostics toward multimodal analysis, which can improve accuracy in early-stage screening.
Human oversight remains central
Despite its AI-driven architecture, Gabify integrates a human-in-the-loop model, ensuring that clinicians validate all AI-generated outputs. This hybrid design aligns with broader healthcare trends, where AI augments rather than replaces clinical expertise.
Reducing time-to-diagnosis
The platform is designed to reduce assessment time by up to 70%, allowing clinicians to manage larger patient volumes without compromising diagnostic quality.
Market forces are accelerating adoption
Several structural trends are converging to support platforms like Gabify.
Rising prevalence and awareness
Post-pandemic estimates suggest autism now affects roughly one in 30 children, increasing demand for scalable screening solutions.
Shortage of trained professionals
India continues to face a significant gap in trained therapists, making traditional diagnosis pathways difficult to scale.
Growth of digital health infrastructure
Government initiatives and private investment are pushing healthcare systems toward digital-first models, particularly in underserved segments such as early intervention.
From product to infrastructure
Gabify is positioning itself as more than a diagnostic tool. Its platform functions as a full-stack ecosystem for screening and therapy management, already tested across more than 35 preschool and daycare centers during its private beta phase.
The system is being adopted by schools, hospitals, private practices, and non-profits, indicating early traction across multiple distribution channels.
Its multilingual, low-bandwidth design also reflects a deliberate focus on accessibility, enabling deployment beyond urban centers and into rural and semi-urban markets.
Expansion strategy and long-term goals
Gabify plans to scale through a combination of institutional partnerships, direct-to-consumer offerings, and CSR-led initiatives. The company has set a target of impacting one million children by 2028, underscoring both the scale of the opportunity and the ambition of its platform.
The broader market context supports this trajectory. The global neurodevelopmental care market is estimated at $110 billion, with strong growth driven by increasing diagnosis rates, rising awareness, and advances in AI-enabled healthcare.
Investor thesis: solving a foundational healthcare problem
For investors, the opportunity lies in addressing a systemic inefficiency. Early diagnosis is not just a clinical milestone — it is a determinant of long-term healthcare costs and outcomes.
By improving access to timely and accurate screening, platforms like Gabify can:
- Enhance intervention success rates
- Reduce long-term treatment costs
- Expand access to quality care
This aligns with a broader shift toward AI-enabled healthcare infrastructure that supports both clinicians and patients at scale.
A broader shift in healthtech innovation
Gabify’s emergence reflects how the healthtech sector is evolving. Earlier waves focused on digitizing access through telemedicine and online consultations. The current phase is increasingly centered on augmenting clinical decision-making itself.
AI is moving deeper into healthcare workflows, supporting diagnosis, treatment planning, and ongoing patient management.
What comes next
Gabify’s next phase will depend on its ability to balance rapid scale with clinical rigor. Expanding AI capabilities while maintaining validation standards will be critical as the platform moves beyond early adopters.
More broadly, its trajectory signals a shift in how pediatric care may be delivered in the future. As healthcare systems adapt to growing demand and limited resources, AI-driven early detection platforms could become a foundational layer of care delivery.
If that transition materializes, companies like Gabify will not just participate in the system — they will help redefine it.
